C188-9 compound: Clinical Trials

7 trials of C188-9 compound, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

2 completed, 2 recruiting, 2 withdrawn, 1 terminated. 5 Phase 1, 3 Phase 2, 1 Early Phase 1.

By phase and status

PhaseTrialsStatus
Phase 15Recruiting 2, Completed 1, Terminated 1, Withdrawn 1
Phase 23Completed 1, Recruiting 1, Withdrawn 1
Early Phase 11Withdrawn 1

Follow C188-9 compound: new trials by email Literature Review of C188-9 compound trials Research Report on C188-9 compound

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Phase I/II Open Label Study Evaluating the Safety and Efficacy of Combining STAT3 Inhibition (TTI-101) With Anti-PD-1 Therapy (Pembrolizumab) in Patients With Recurrent or Metastatic (RM) Head and Neck Squamous Cell Carcinoma (HNSCC)
TTI-101, Pembrolizumab - Head and Neck Squamous Cell Carcinoma
Phase 1 / Phase 2WithdrawnM.D. Anderson Cancer Center2025-09-232025-12-17
Randomized Pre-surgical Window-of-Opportunity Trial of TTI-101 in Patients With Stage II-IV Resectable HPV-negative Squamous Cell Carcinoma of the Head and Neck
Control Group, TTI-101 - Squamous Cell Carcinoma of Head and Neck
Early Phase 1WithdrawnM.D. Anderson Cancer Center2025-06-202025-12-08
Radiotherapy in Combination With TTI-101 in Borderline Resectable and Locally Advanced Pancreatic Ductal Adenocarcinoma
TTI-101, Stereotactic body radiation therapy - Pancreatic Cancer
Phase 1RecruitingWashington University School of Medicine242024-01-162026-11-06
Study of TTI-101 in Participants With Idiopathic Pulmonary Fibrosis
TTI-101, Placebo - Idiopathic Pulmonary Fibrosis
Phase 2CompletedTvardi Therapeutics, Incorporated1002023-05-152026-08-13
A Study of TTI-101 as Monotherapy and in Combination in Participants With Locally Advanced or Metastatic, and Unresectable Hepatocellular Carcinoma
TTI-101, Pembrolizumab, Atezolizumab - Hepatocellular Carcinoma
Phase 1 / Phase 2RecruitingTvardi Therapeutics, Incorporated1932023-03-232026-10-22
Phase 1b/2 Study of TTI-101 in Combination for Patients With Metastatic Hormone Receptor-Positive and HER2-Negative Breast Cancer
TTI-101, Palbociclib, Aromatase inhibitor (AI) - Breast Cancer
Phase 1TerminatedTvardi Therapeutics, Incorporated62023-01-092026-09-24
Oral STAT3 Inhibitor, TTI-101, in Patients With Advanced Cancers
TTI-101 - Breast Cancer, Head and Neck Squamous Cell Carcinoma
Phase 1CompletedTvardi Therapeutics, Incorporated642017-11-152025-03-21

Conditions studied

Squamous Cell Carcinoma of Head and Neck (3)  ·  Breast Neoplasms (2)  ·  Carcinoma, Hepatocellular (1)  ·  Carcinoma, Non-Small-Cell Lung (1)  ·  Colorectal Neoplasms (1)  ·  Idiopathic Pulmonary Fibrosis (1)  ·  Liver Neoplasms (1)  ·  Melanoma (1)  ·  Neoplasms (1)  ·  Pancreatic Neoplasms (1)

Sponsors

Tvardi Therapeutics, Incorporated (4)  ·  M.D. Anderson Cancer Center (2)  ·  Washington University School of Medicine (1)

Countries

United States (5)

Top investigators

Andrew Sikora, MD,PHD (1)  ·  Apostolia Tsimberidou, MD, PhD (1)  ·  Faye Johnson, MD (1)  ·  Sana Karam, M.D., Ph.D. (1)

Results publications

PMID 39792482

NIH funding

R01CA255960 (1)